General Information of This Peptide-drug Conjugate (PDC)
PDC ID
PDC_00063
PDC Name
ANG-PTX
PDC Status
Investigative
Indication
In total 1 Indication(s)
Central nervous system disease
Structure
Peptide Name
Angiopep-2
 Peptide Info 
Receptor Name
Prolow-density lipoprotein receptor-related protein 1; Low-density lipoprotein receptor-related protein 2 (LRP1; LRP2)
 Receptor Info 
Drug Name
Paclitaxel
 Drug Info 
Therapeutic Target
Microtubule (MT)
 Target Info 
Linker Name
Ester bond
 Linker Info 
Formula
C161H212N32O47S
#Ro5 Violations (Lipinski): 5 Molecular Weight 3379.711
Lipid-water partition coefficient (xlogp) -6.7264
Hydrogen Bond Donor Count (hbonddonor) 39
Hydrogen Bond Acceptor Count (hbondacc) 51
Rotatable Bond Count (rotbonds) 101
Full List of Activity Data of This Peptide-drug Conjugate
Revealed Based on the Cell Line Data
Click To Hide/Show 2 Activity Data Related to This Level
Experiment 1 Reporting the Activity Data of This PDC [1]
Indication Central nervous system disease
Efficacy Data Inhinition rate
33.21 ± 3.32%
Administration Time 24 h
In Vitro Model Glioblastoma U87 cell CVCL_3429
Experiment 2 Reporting the Activity Data of This PDC [1]
Indication Central nervous system disease
Efficacy Data Inhinition rate
50.24 ± 4.75%
Administration Time 48 h
In Vitro Model Glioblastoma U87 cell CVCL_3429
References
Ref 1 Delivery of a peptide-drug conjugate targeting the blood brain barrier improved the efficacy of paclitaxel against glioma. Oncotarget. 2016 Nov 29;7(48):79401-79407. doi: 10.18632/oncotarget.12708.